scispace - formally typeset
F

Frederick T. Chin

Researcher at Stanford University

Publications -  144
Citations -  3747

Frederick T. Chin is an academic researcher from Stanford University. The author has contributed to research in topics: Positron emission tomography & In vivo. The author has an hindex of 34, co-authored 136 publications receiving 3123 citations. Previous affiliations of Frederick T. Chin include University of Missouri & National Institutes of Health.

Papers
More filters
Journal ArticleDOI

Click Chemistry for 18F-Labeling of RGD Peptides and microPET Imaging of Tumor Integrin αvβ3 Expression

TL;DR: The use of the Cu(I)-catalyzed Huisgen cycloaddition, also known as a click reaction, to label RGD peptides with 18F by forming 1,2,3-triazoles is reported.
Journal ArticleDOI

Persistent dopamine functions of neurons derived from embryonic stem cells in a rodent model of Parkinson disease.

TL;DR: After transplantation into an animal model, neurons derived from mouse ES cells survived for over 32 weeks, maintained midbrain markers, and had sustained behavioral effects, suggesting that ES cell‐derived neurons show DA release and reuptake and stimulate appropriate postsynaptic responses for long periods after implantation.
Journal ArticleDOI

Pilot Comparison of ⁶⁸Ga-RM2 PET and ⁶⁸Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer.

TL;DR: 68Ga-PSMA-11 and 68Ga-RM2 had distinct biodistributions in this small cohort of patients with biochemically recurrent prostate cancer and additional work is needed to understand the expression of PSMA and gastrin-releasing peptide receptors in different types of prostate cancer.
Journal ArticleDOI

18F-labeled galacto and PEGylated RGD dimers for PET imaging of αvβ3 integrin expression.

TL;DR: Dimeric RGD peptide tracers with relatively high tumor integrin-specific accumulation and favorable in vivo kinetics may have the potential to be translated into clinic for integrin αvβ3 imaging.
Journal ArticleDOI

Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging α(v)β(3) integrin levels.

TL;DR: The administration of (18)F-FPPRGD2 was well tolerated, with no marked effects on vital signs, ECG readings, or laboratory values, and tracer biodistribution and dosimetric properties, time-activity curves, and the stability of laboratory values were evaluated.